Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Combination Details

General Information of the Combination (ID: C43091)
Name Triamcinolone   NP Info  + 5-fluorouracil   Drug Info 
Structure +
Disease
Keloidscars [ICD-11: N.A.]
Phase 4 [1]
Keloids [ICD-11: EE60]
Investigative [2]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    Molecule(s)
                    Regulation
Down-regulation Expression COL1A1  Molecule Info 
Pathway MAP
Down-regulation Expression TGFB1  Molecule Info 
Pathway MAP
                    Biological
                    Regulation
Induction Cell cycle arrest in G2 phase
                    In-vitro Model Keloid fibroblasts Healthy Homo sapiens
                    Experimental
                    Result(s)
Combination of TA and 5-FU showed synergistic interation in regulating the biological behaviour of keloid fibroblasts in vitro.
References
Reference 1 ClinicalTrials.gov (NCT02155439) Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study.
Reference 2 A study of the combination of triamcinolone and 5-fluorouracil in modulating keloid fibroblasts in vitro. J Plast Reconstr Aesthet Surg. 2013 Sep;66(9):e251-9.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China